NCT04285723 - Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)

Interventions

OTHER

alpelisib

Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.

Trial Locations (7)

12

Novartis Investigative Site, Dublin

3052

Novartis Investigative Site, Parkville

21000

Novartis Investigative Site, Dijon

28046

Novartis Investigative Site, Madrid

34059

Novartis Investigative Site, Montpellier

75015

Novartis Investigative Site, Paris

02215

Boston Childrens Hospital, Boston